<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph" /><meta name="keywords" content="Combined hormonal contraceptives; Oral contraceptives see Contraception, oral; Contraception: oral: starting routines; Contraception: transdermal: starting routines" /><meta name="IX" content="Combined hormonal contraceptives; Contraception: oral: starting routines; Contraception: transdermal: starting routines" /><meta name="IXN" content="Oral contraceptives see Contraception, oral" /><title>COMBINED HORMONAL CONTRACEPTIVES: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP4879-combined-hormonal-contraceptives.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP4879-combined-hormonal-contraceptives.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP4879-combined-hormonal-contraceptives.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP4758-obstetrics-gynaecology-and-urinary-tract-disorders.htm">7 Obstetrics, gynaecology, and urinary-tract disorders</a> &gt; <a href="PHP4853-contraceptives.htm">7.3 Contraceptives</a> &gt; <a href="PHP4869-combined-hormonal-contraceptives.htm">7.3.1 Combined hormonal contraceptives</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP4869-combined-hormonal-contraceptives.htm" title="Previous: 7.3.1 Combined hormonal contraceptives">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP4894-oral-low-and-standard-strength.htm" title="Next: Oral (low and standard strength)">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>COMBINED HORMONAL CONTRACEPTIVES</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int1172-dienogest.htm">Dienogest</a>,<a href="bnf_int673-norethisterone.htm">Norethisterone</a>,<a href="bnf_int665-desogestrel.htm">Desogestrel</a>,<a href="bnf_int638-ethinylestradiol.htm">Ethinylestradiol</a>,<a href="bnf_int639-mestranol.htm">Mestranol</a>,<a href="bnf_int668-gestodene.htm">Gestodene</a>,<a href="bnf_int972-norelgestromin.htm">Norelgestromin</a>,<a href="bnf_int962-drospirenone.htm">Drospirenone</a>,<a href="bnf_int674-norgestimate.htm">Norgestimate</a>,<a href="bnf_int671-levonorgestrel.htm">Levonorgestrel</a>,<a href="bnf_int890-etonogestrel.htm">Etonogestrel</a>,<a href="bnf_int640-estradiol.htm">Estradiol</a>).</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Indications </h2> <p class="cT">contraception; menstrual symptoms (<a title=" Progestogens" href="PHP4486-progestogens-and-progesterone-receptor-modulators.htm">section 6.4.1.2</a>)</p></div> </div> <div id="PHP4880" class="cL"><div class="cE"><h2 class="cN">Cautions </h2> <p class="cT">see <a title="sub-section: Combined hormonal contraceptives" href="PHP4869-combined-hormonal-contraceptives.htm">notes above</a>; risk factors for venous thromboembolism (see below and also <a title="target-block: contraceptives and risk of venous thromboembolism" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4870">notes above</a>), arterial disease and migraine, see below; personal or family history of hypertriglyceridaemia (increased risk of pancreatitis); hyperprolactinaemia (seek specialist advice); history of severe depression especially if induced by hormonal contraceptive; undiagnosed breast mass; gene mutations associated with breast cancer (e.g. BRCA 1); sickle-cell disease; inflammatory bowel disease including Crohn's disease; reduced efficacy of contraceptive patch in women with body-weight ≥ 90 kg; active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice; <strong>interactions:</strong>  <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">see above</a> and Appendix 1 (oestrogens, progestogens)</p></div> <div class="cG"><div class="cE"><h3 class="cT">Risk factors for venous thromboembolism</h3> <p class="cT">See also <a title="target-block: contraceptives and risk of venous thromboembolism" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4870">notes above</a>. Use with <strong>caution</strong> if any of following factors present but <strong>avoid</strong> if two or more factors present:</p></div><ul><li><p><em>family history of venous thromboembolism</em> in first-degree relative aged under 45 years (avoid contraceptive containing desogestrel or gestodene, <em>or</em> avoid if known prothrombotic coagulation abnormality e.g. factor V Leiden or antiphospholipid antibodies (including lupus anticoagulant));</p> </li><li><p><em>obesity</em>—body mass index ≥ 30 kg/m<sup>2</sup> (avoid if body mass index ≥ 35 kg/m<sup>2</sup> unless no suitable alternative);</p> </li><li><p><em>long-term immobilisation</em> e.g. in a wheelchair (avoid if confined to bed or leg in plaster cast);</p> </li><li><p><em>history of superficial thrombophlebitis</em>;</p> </li><li><p><em>age</em> over 35 years (avoid if over 50 years);</p> </li><li><p><em>smoking</em>.</p> </li></ul></div> <div id="PHP4886" class="cG"><div class="cE"><h3 class="cT">Risk factors for arterial disease</h3> <p class="cT">Use with <strong>caution</strong> if any one of following factors present but <strong>avoid</strong> if two or more factors present:</p></div><ul><li><p><em>family history of arterial disease</em> in first degree relative aged under 45 years (avoid if atherogenic lipid profile);</p> </li><li><p><em>diabetes mellitus</em> (avoid if diabetes complications present);</p> </li><li><p><em>hypertension</em>—blood pressure above <em>systolic 140 mmHg</em> or <em>diastolic 90 mmHg</em> (avoid if blood pressure above <em>systolic 160 mmHg</em> or <em>diastolic 95 mmHg</em>);</p> </li><li><p><em>smoking</em> (avoid if smoking 40 or more cigarettes daily);</p> </li><li><p><em>age</em> over 35 years (avoid if over 50 years);</p> </li><li><p><em>obesity</em> (avoid if body mass index ≥ 35 kg/m<sup>2</sup> unless no suitable alternative);</p> </li><li><p><em>migraine without aura </em>(avoid if <em>migraine with aura </em>(focal symptoms), <em>or</em> severe migraine frequently lasting over 72 hours despite treatment,<em> or </em>migraine treated with ergot derivatives).</p> </li></ul></div> <div class="cG"><div class="cE"><h3 class="cT">Migraine</h3> <p class="cT">Women should report any increase in headache frequency or onset of focal symptoms (discontinue immediately and refer urgently to neurology expert if focal neurological symptoms not typical of aura persist for more than 1 hour—see also <a title="target-block: hrt reasons to stop" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4878">Reason To Stop Immediately</a> in notes above)</p></div></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Contra-indications </h2> <p class="cT">see <a title="sub-section: Combined hormonal contraceptives" href="PHP4869-combined-hormonal-contraceptives.htm">notes above</a>; personal history of venous or arterial thrombosis, severe or multiple risk factors for arterial disease or for venous thromboembolism (see above), heart disease associated with pulmonary hypertension or risk of embolus; sclerosing treatment for varicose veins; migraine with aura (see also <a title="target-block: COC cautions (b)" href="PHP4879-combined-hormonal-contraceptives.htm#PHP4886">above</a>); transient cerebral ischaemic attacks without headaches; systemic lupus erythematosus with (or unknown) antiphospholipid antibodies; acute porphyria (<a title=" Acute porphyrias" href="PHP6363-acute-porphyrias.htm">section 9.8.2</a>); gallstones; history of haemolytic uraemic syndrome or history during pregnancy of pruritus, cholestatic jaundice, chorea, pemphigoid gestationis; history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable; undiagnosed vaginal bleeding</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Hepatic impairment </h2> <p class="cT">avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Pregnancy </h2> <p class="cT">not known to be harmful</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Breast-feeding </h2> <p class="cT">avoid until weaning or for 6 months after birth (adverse effects on lactation)</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Side-effects </h2> <p class="cT">see <a title="sub-section: Combined hormonal contraceptives" href="PHP4869-combined-hormonal-contraceptives.htm">notes above</a>; also nausea, vomiting, abdominal cramps, liver impairment, hepatic tumours; fluid retention, thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB; see also notes above), hypertension, changes in lipid metabolism; headache, depression, chorea, nervousness, irritability; changes in libido, breast tenderness, enlargement, and secretion; reduced menstrual loss, ‘spotting’ in early cycles, absence of withdrawal bleeding, amenorrhoea after discontinuation, changes in vaginal discharge, cervical erosion; contact lenses may irritate, visual disturbances; leg cramps; skin reactions, chloasma, photosensitivity; rarely gallstones and systemic lupus erythematosus</p></div> <div class="cG"><div class="cE"><h3 class="cT">Breast cancer</h3> <p class="cT">There is a small increase in the risk of having breast cancer diagnosed in women taking the combined oral contraceptive pill; this relative risk may be due to an earlier diagnosis. In users of combined oral contraceptive pills the cancers are more likely to be localised to the breast. The most important factor for diagnosing breast cancer appears to be the age at which the contraceptive is stopped rather than the duration of use; any increase in the rate of diagnosis diminishes gradually during the 10 years after stopping and disappears by 10 years</p></div></div> <div id="PHP4890" class="cG"><div class="cE"><h3 class="cT">Cervical cancer</h3> <p class="cT">Use of combined oral contraceptives for 5 years or longer is associated with a small increased risk of cervical cancer; the risk diminishes after stopping and disappears by about 10 years. The risk of cervical cancer with transdermal patches and vaginal rings is not yet known</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">The possible small increase in the risk of breast cancer and cervical cancer should be weighed against the protective effect against cancers of the ovary and endometrium</p></div></div> </div> <div class="cL"><h2 class="cM">Dose</h2><div class="cR"><ul> <li><p id="PHP4891"><span class="cK">By mouth</span> , each tablet should be taken at approximately same time each day; if delayed, contraceptive protection may be lost (see <a title="BNF:target-block: Missed pill" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4872">missed pill</a>)</p> <p><em>21-day combined (monophasic) preparations</em>, 1 tablet daily for 21 days; subsequent courses repeated after a 7-day interval (during which withdrawal bleeding occurs); if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days</p> <p><em>Every day (ED) combined (monophasic) preparations</em>, 1 <em>active</em> tablet daily for 21 days, followed by 1 <em>inactive</em> tablet daily for 7 days (see also Combined Oral Contraceptives <a title="BNF:preparation-family: Oral (low and standard strength)" href="PHP4894-oral-low-and-standard-strength.htm">table</a>, below); subsequent courses repeated without interval (withdrawal bleeding occurs when <em>inactive</em> tablets being taken); if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days</p> <p><em>Phasic preparations</em>, see Combined Oral Contraceptives <a title="BNF:preparation-family: Oral (low and standard strength)" href="PHP4894-oral-low-and-standard-strength.htm">table</a>, below</p> <div class="cG"><div class="cE"><h3 class="cT">Changing to combined preparation containing different progestogen</h3> <p class="cT">If previous contraceptive used correctly, or pregnancy can reasonably be excluded, start the first <em>active</em> tablet of new brand immediately</p></div><p><em>Changing to Qlaira®</em>: start the first<em> active Qlaira®</em> tablet on the day after taking the last active tablet of the previous brand</p><p><em>Changing from Qlaira®</em>: start the new brand after taking the last active <em>Qlaira®</em> tablet; if the inactive tablets are taken before starting new brand, additional precautions (barrier methods) should be used during first 7 days of taking the new brand</p></div> <div class="cG"><div class="cE"><h3 class="cT">Changing from progestogen-only tablet</h3> <p class="cT">If previous contraceptive used correctly, or pregnancy can reasonably be excluded, start new brand immediately, additional precautions (barrier methods) necessary for first 7 days</p></div><p><em>Changing to Qlaira®</em>: start any day, additional precautions (barrier methods) necessary for first 9 days</p></div> <div class="cG"><div class="cE"><h3 class="cT">Secondary amenorrhoea (exclude pregnancy)</h3> <p class="cT">Start any day, additional precautions (barrier methods) necessary during first 7 days (9 days for <em>Qlaira</em>®)</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">After childbirth (not breast-feeding)</h3> <p class="cT">Start 3 weeks after birth (increased risk of thrombosis if started earlier); later than 3 weeks postpartum additional precautions (barrier methods) necessary for first 7 days (9 days for <em>Qlaira</em>®)</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">After abortion or miscarriage</h3> <p class="cT">Start same day</p></div></div> </li> <li> <p id="PHP4892"><span class="cK">By transdermal application</span>, apply first patch on day 1 of cycle, change patch on days 8 and 15; remove third patch on day 22 and apply new patch after 7-day patch-free interval to start subsequent contraceptive cycle</p> <div class="cG"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">If first patch applied later than day 1, additional precautions (barrier methods) should be used for the next 7 days</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">Changing from combined oral contraception</h3> <p class="cT">Apply patch on the first day of withdrawal bleeding; if no withdrawal bleeding within 5 days of taking last <em>active</em> tablet, rule out pregnancy before applying first patch. Unless patch is applied on first day of withdrawal bleeding, additional precautions (barrier methods) should be used concurrently for first 7 days</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">Changing from progestogen-only method</h3> <p class="cT">From an implant, apply first patch on the day implant removed; from an injection, apply first patch when next injection due; from oral progestogen, first patch may be applied on any day after stopping pill. For all methods additional precautions (barrier methods) should be used concurrently for first 7 days </p></div></div> <div class="cG"><div class="cE"><h3 class="cT">After childbirth (not breast-feeding)</h3> <p class="cT">Start 4 weeks after birth; if started later than 4 weeks after birth additional precautions (barrier methods) should be used for first 7 days</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">After abortion or miscarriage</h3> <p class="cT">Before 20 weeks' gestation start immediately; no additional contraception required if started immediately. After 20 weeks' gestation start on day 21 after abortion or on the first day of first spontaneous menstruation; additional precautions (barrier methods) should be used for first 7 days after applying the patch</p></div></div> </li> <li><p id="PHP4893"><span class="cK">By vagina</span>, insert ring into vagina on day 1 of cycle and leave in for 3 weeks; remove ring on day 22; subsequent courses repeated after 7-day ring-free interval (during which withdrawal bleeding occurs) </p> <div class="cG"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">If first ring inserted later than day 1, additional precautions (barrier methods) should be used for the next 7 days</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">Changing from combined hormonal contraception</h3> <p class="cT">Insert ring at the latest on the day after the usual tablet-free, patch-free, or inactive-tablet interval. If previous contraceptive used correctly, or pregnancy can reasonably be excluded, can switch to ring on any day of cycle</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">Changing from progestogen-only method</h3> <p class="cT">From an implant or intra-uterine progestogen-only device, insert ring on the day implant or intra-uterine progestogen-only device removed; from an injection, insert ring when next injection due; from oral preparation, first ring may be inserted on any day after stopping pill. For all methods additional precautions (barrier methods) should be used concurrently for first 7 days</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">After first trimester abortion</h3> <p class="cT">Start immediately</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">After childbirth (not breast-feeding) or second trimester abortion</h3> <p class="cT">Start 4 weeks after birth or abortion; if started later than 4 weeks after birth or abortion, additional precautions (barrier methods) should be used for first 7 days</p></div></div> </li> </ul></div></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP4894-oral-low-and-standard-strength"><a href="PHP4894-oral-low-and-standard-strength.htm" title="Oral (low and standard strength)">Oral (low and standard strength)</a></li><li id="_PHP4937-transdermal-standard-strength"><a href="PHP4937-transdermal-standard-strength.htm" title="Transdermal (standard strength)">Transdermal (standard strength)</a></li><li id="_PHP4940-vaginal-low-strength"><a href="PHP4940-vaginal-low-strength.htm" title="Vaginal (low strength)">Vaginal (low strength)</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP4869-combined-hormonal-contraceptives.htm">Previous: 7.3.1 Combined hormonal contraceptives</a> | <a class="top" href="PHP4879-combined-hormonal-contraceptives.htm#">Top</a> | <a accesskey="]" href="PHP4894-oral-low-and-standard-strength.htm">Next: Oral (low and standard strength)</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>